MarketPeel
Insider Trading Intelligence
Pricing
…
DA

Daljit Singh Aurora

NMRA
CHIEF STRATEGY OFFICER · NEUMORA THERAPEUTICS, INC. · CIK 0001793971
FILING MIX · LIFETIME38%/62%
BUYS
22
SELLS
36
TOTAL VALUE
$907.5K
COMPANIES
2
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
82,770
AVG SELL PX
$5.69
TRADE KIND
SHOWING 58 / 58
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 6 pending
Forward-return performance of every backtestable P/S trade by Daljit Singh Aurora, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+100.00%-3.48%-1.84%-1.64%-1.23%—
14d3+100.00%-16.75%-2.40%-14.35%-13.19%—
30d3+100.00%-28.36%-3.33%-25.03%-25.43%—
60d3+100.00%-40.38%-2.68%-37.70%-43.26%—
90d3+100.00%-39.87%+2.63%-42.50%-55.18%—
180d3(1 pending)+100.00%-18.60%+6.88%-25.48%-25.48%—
1y3(2 pending)+0.00%+107.51%+12.57%+94.94%+94.94%—
2y3(3 pending)——————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NMRA · 82,770 shares · as of Feb 17, 2026
0250,000500,000750,0001,000,00020252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 22 buys / 36 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
6,165$3.56$21.9K82,770Feb 17, 2026Feb 19, 2026 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
750,000——750,000Jan 8, 2026Jan 9, 2026 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
114,703$2.68$307.0K0Nov 11, 2025Nov 13, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
136,210——136,210May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,000,000——1,000,000May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
137,538——137,538May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
40,890——0May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
72,221——0May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
207,901——0May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
195,000——0May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
29,737——29,737May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
29,737——0May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
137,538——0May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
72,221——72,221May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
195,000——195,000May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
207,901——207,901May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
40,890——40,890May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
1,000,000——0May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
136,210——0May 28, 2025May 30, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,565$1.68$14.3K88,935Feb 18, 2025Feb 20, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
137,538——0Feb 13, 2025Feb 18, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
136,210——136,210Feb 13, 2025Feb 18, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
29,737——0Feb 13, 2025Feb 18, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
137,538——137,538Feb 13, 2025Feb 18, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
195,000——195,000Feb 13, 2025Feb 18, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,000,000——1,000,000Feb 13, 2025Feb 18, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
72,221——72,221Feb 13, 2025Feb 18, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
40,890——0Feb 13, 2025Feb 18, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
136,210——0Feb 13, 2025Feb 18, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
207,901——0Feb 13, 2025Feb 18, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
207,901——207,901Feb 13, 2025Feb 18, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
40,890——40,890Feb 13, 2025Feb 18, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
29,737——29,737Feb 13, 2025Feb 18, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
72,221——0Feb 13, 2025Feb 18, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
See Remarks
195,000——0Feb 13, 2025Feb 18, 2025 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Gift
29,737——29,737Sep 12, 2024Sep 13, 2024 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Gift
137,538——137,538Sep 12, 2024Sep 13, 2024 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALEGRANT
Gift
29,737——72,221Sep 12, 2024Sep 13, 2024 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALEGRANT
Gift
137,538——40,890Sep 12, 2024Sep 13, 2024 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Gift
136,210——136,210Sep 12, 2024Sep 13, 2024 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALEGRANT
Gift
136,210——207,901Sep 12, 2024Sep 13, 2024 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALEGRANT
Gift
114,703——97,500Apr 22, 2024Apr 24, 2024 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
97,500——212,203Feb 14, 2024Feb 16, 2024 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
195,000——195,000Feb 14, 2024Feb 16, 2024 ↗View →
DERM
JOURNEY MEDICAL CORP
SALE
Chief Scientific Affairs Off
10,000——0Feb 20, 2020Feb 24, 2020 ↗View →
DERM
JOURNEY MEDICAL CORP
SALE
Chief Scientific Affairs Off
67,500——0Feb 20, 2020Feb 24, 2020 ↗View →
DERM
JOURNEY MEDICAL CORP
SALE
Chief Scientific Affairs Off
28,130——0Feb 20, 2020Feb 24, 2020 ↗View →
DERM
JOURNEY MEDICAL CORP
SALE
Chief Scientific Affairs Off
22,500——0Feb 20, 2020Feb 24, 2020 ↗View →
DERM
JOURNEY MEDICAL CORP
SALE
Chief Scientific Affairs Off
708——0Feb 20, 2020Feb 24, 2020 ↗View →
DERM
JOURNEY MEDICAL CORP
SALE
Chief Scientific Affairs Off
6,000——0Feb 20, 2020Feb 24, 2020 ↗View →
DERM
JOURNEY MEDICAL CORP
SALE
Chief Scientific Affairs Off
11,500——0Feb 20, 2020Feb 24, 2020 ↗View →
DERM
JOURNEY MEDICAL CORP
SALE
Chief Scientific Affairs Off
50,000——0Feb 20, 2020Feb 24, 2020 ↗View →
DERM
JOURNEY MEDICAL CORP
SALE
Chief Scientific Affairs Off
574——0Feb 20, 2020Feb 24, 2020 ↗View →
DERM
JOURNEY MEDICAL CORP
SALE
Chief Scientific Affairs Off
7,040——0Feb 20, 2020Feb 24, 2020 ↗View →
DERM
JOURNEY MEDICAL CORP
SALE
Chief Scientific Affairs Off
6,250——0Feb 20, 2020Feb 24, 2020 ↗View →
DERM
JOURNEY MEDICAL CORP
SALE
Chief Scientific Affairs Off
28,000——0Feb 20, 2020Feb 24, 2020 ↗View →
DERM
JOURNEY MEDICAL CORP
SALE
Chief Scientific Affairs Off
30,089$18.75$564.2K0Feb 20, 2020Feb 24, 2020 ↗View →
DERM
JOURNEY MEDICAL CORP
SALE
Chief Scientific Affairs Off
2,814——0Feb 20, 2020Feb 24, 2020 ↗View →
Other insiders · NMRA
Loading peer insiders…
About this filer
CIK 0001793971
ROLE
Chief Strategy Officer
PRIMARY
NMRA
COMPANIES
2
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001793971DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback